HomeClinical TopicsFDA approves new indication for imaging agent

FDA approves new indication for imaging agent

On June 13, the U.S. Food and Drug Administration (FDA) a new use for Lymphoseek (technetium 99m tilmanocept) Injection, a radioactive diagnostic imaging agent used to help determine the extent that squamous cell carcinoma has spread in the body’s head and neck region. Lymphoseek can now be used to guide “sentinel” lymph node biopsy in patients with cancer of the head and neck. This new indication will allow for the option of more limited lymph node surgery in patients with sentinel nodes negative for cancer. Read more.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Recent Content

For Nurse Practitioners

Couple talking to NP

Getting Covid Vaccine Won’t Hurt Pregnancy Chances; Getting Covid Could

Couples planning a pregnancy might be relieved to know that getting a Covid vaccine does not hurt their odds of conceiving, according to the...